© 2020 MJH Life Sciences and HCPLive. All rights reserved.
Asthma
Benralizumab Safe, Effective for Asthma Patients
August 10, 2020
Article
Results of ANDHI provide additional support on the safety and efficacy of benralizumab for patients with asthma.
Dupilumab Reduces Asthma Exacerbation Rates
August 08, 2020
Article
Dupilumab significantly reduces exacerbation rates in patients with asthma compared to standard of care.
GDC-0214 Well-Tolerated for Patients with Mild Asthma
August 08, 2020
Article
In a study presented virtually at ATS 2020, investigators find 15 mg of the study drug resulted in a 43% decrease in FeNO.
Autopsies, Biopsies Link Lung Injuries to E-Cigarette Use
August 07, 2020
Article
A new case study assesses biopsy and autopsy tissues to characterize pathological patterns in suspected EVALI cases .
Tezepelumab Helps Reduce Severe Asthma Exacerbations
August 07, 2020
Article
In a study presented at ATS 2020, investigators test 3 different dosing regimens of tezepelumab in asthma patients with both high and low levels of IL-5 and IL-13.
Nirsevimab Shows Promise in Preventing RSV Infections in Preterm-Born Infants
August 06, 2020
Article
A one-time intramuscular dose of the investigative drug was linked to reduced medical attention and hospitalizations related to RSV.
Older, Male Asthmatics at Greater COVID-19 Severity Risk
August 05, 2020
Article
New findings suggest differing chronic lung diseases are associated with varying risk factors among COVID-19 patients.
Very Early Spring Onset Associated With Asthma-Related Hospital Admissions
July 07, 2020
Article
There is also an association between late onset of spring and an increase in hospital admissions for asthma.
Developmental Disabilities Linked to Greater Pediatric Asthma Risk
July 02, 2020
Article
ADHD, autism spectrum disorder, seizures, and even developmental delays are asssociated with a two-fold risk of asthma in US children.
FDA Approves Pre-Filled Dupilumab Pen
June 19, 2020
Article
The FDA is allowing the pen to be used for the treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis (CRSwNP) patients at least 12 years old.